Uma Mahadevan, MD

Gastroenterologist

An expert in inflammatory bowel disease, particularly as it relates to pregnancy and fertility, new drug trials and pouchitis, Dr. Uma Mahadevan serves as co-medical director of the UCSF Center for Colitis and Crohn's disease. In addition to caring for patients with inflammatory bowel disease (IBD), she is interested in developing novel therapies for the condition, as well as investigating pregnancy and fertility outcomes in IBD.

Mahadevan received her medical degree from State University of New York and completed her residency in internal medicine at Mount Sinai Medical Center in New York. She then went on to complete her fellowship in gastroenterology at UCSF and in inflammatory bowel disease at Mayo Clinic, Rochester, Minn. Her research on inflammatory bowel disease has been widely published in medical journals and books. Currently, Mahadevan holds the position of professor of clinical medicine at UCSF.

Clinics

Colitis and Crohn's Disease Center
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 353-7921
Fax: (415) 502-2249

Gastroenterology at Mount Zion
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Conditions & Treatments

  • Microscopic Colitis
  • Pouchitis

Board Certification

Gastroenterology, American Board of Internal Medicine

Academic Title

Professor

More about Uma Mahadevan

Additional Languages

Tamil

Education

State University of New York, Brooklyn College of Medicine 1995

Residencies

Mount Sinai Medical Center, Internal Medicine 1998

Fellowships

Mayo Clinic, Inflammatory Bowel Disease 2001
UCSF Medical Center, Gastroenterology 2001

Selected Research and Publications

  1. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women with Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2017 Sep 01.
  2. Bengtson MB, Aamodt G, Mahadevan U, Vatn MH. Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study. Inflamm Bowel Dis. 2017 Jul; 23(7):1225-1233.
  3. Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply. Aliment Pharmacol Ther. 2017 May; 45(9):1284.
  4. Mahadevan U. How to Get an Education in Inflammatory Bowel Disease During Fellowship: Expectations and Realities. Gastroenterology. 2017 Jun; 152(8):1813-1816.
  5. Bengtson MB, Martin CF, Aamodt G, Vatn MH, Mahadevan U. Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort. Dig Dis Sci. 2017 Aug; 62(8):2063-2069.
  6. Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr; 45(7):941-950.
  7. Colombel JF, Mahadevan U. Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. Gastroenterology. 2017 Feb; 152(2):309-312.
  8. Mahadevan U, McConnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology. 2017 Feb; 152(2):451-462.e2.
  9. Mar JS, LaMere BJ, Lin DL, Levan S, Nazareth M, Mahadevan U, Lynch SV. Disease Severity and Immune Activity Relate to Distinct Interkingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients. MBio. 2016 Aug 16; 7(4).
  10. McConnell RA, Mahadevan U. The Birds, the Bees, and Inflammatory Bowel Disease: Preconception Care in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):1293-5.
  11. Cohan JN, Ozanne EM, Sewell JL, Hofer RK, Mahadevan U, Varma MG, Finlayson E. A Novel Decision Aid for Surgical Patients with Ulcerative Colitis: Results of a Pilot Study. Dis Colon Rectum. 2016 Jun; 59(6):520-8.
  12. McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016 06; 45(2):285-301.
  13. Kathpalia P, Kane S, Mahadevan U. Detectable Drug Levels in Infants Exposed to Biologics: So What? Gastroenterology. 2016 Jul; 151(1):25-6.
  14. Carlucci JG, Halasa N, Creech CB, Dulek DE, Gómez-Duarte OG, Nelson GE, Talbot HK, Scalise ML, Scott PL, Mahadevan U, Beaulieu DB. Vertical Transmission of Histoplasmosis Associated With Anti-Tumor Necrosis Factor Therapy. J Pediatric Infect Dis Soc. 2016 Jun; 5(2):e9-e12.
  15. Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 Jun; 61(6):1622-7.
  16. McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016 Jan; 22(1):213-23.
  17. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar; 150(3):734-757.e1.
  18. Mahadevan U, Matro R. In Reply. Obstet Gynecol. 2015 Nov; 126(5):1109.
  19. Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol. 2015 Dec; 42(12):2270-8.
  20. Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstet Gynecol. 2015 Aug; 126(2):401-12.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.